Cancer - Side effect drugs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cancer - Side effect drugs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who started this subject	5/18/2002 1:33:24 PM
From: John McCarthy	of 57

[2002]-[BNP7787]-[BioNumerik Pharmaceuticals] BioNumerik Pharmaceuticals crunches the numbers to develop drugs that fight cancer and the side effects associated with many therapies. The firm relies heavily on computer models and simulations to identify promising drug candidates. It accesses supercomputer technology through an alliance with Cray. Lead candidate BNP7787 may prevent nerve and kidney damage caused by cancer treatments and has been granted FDA fast-track development status. Most of the firm's revenue is from a joint venture with an affiliate of Japanese drugmaker Takeda Chemical Industries. Partner ASTA Medica of Germany will market BNP7787 in Europe and other select areas. Founder and chairman Frederick Hausheer owns nearly a third of BioNumerik. Top Competitors Aventis Pharmaceuticals \| ILEX \| Sepracor More Competitors Extensive Lists, Handpicked By Our Editors hoovers.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next